An integrated semi-mechanistic pharmacodynamic (PD) model describing the relationship between luteinizing hormone (LH) and testosterone (T) after short-term administration of degarelix was developed. Data from three clinical studies involving, intravenous (IV) and subcutaneous (SC) dosing, in healthy male subjects were available. Degarelix pharmacokinetic (PK) data from all studies were modeled simultaneously. One intravenous study was used to develop the PD model and the two other studies (IV and SC dosing) were used to qualify the model. Degarelix PK follows a two-compartment model and exhibits flip-flop kinetics after subcutaneous dosing. Based on physiological mechanism, the gonadotropin releasing hormone (GnRH) time course was described using a pulsatile release model. A precursor-dependent pool model was used to describe the kinetics of LH in the pituitary and plasma compartment. In males, LH regulates T production in leydig cells. Degarelix inhibits the release of LH from the pool compartment to the plasma compartment leading to decreased T production. The plasma half-life of LH (2.6–3.3 hr) and T (2.7 hr) match well with the literature reports. The proposed PD model reasonably described the time course of LH and T including the LH rebound for short-term studies. The model predicted the time course of LH and T for the second IV and SC dosing studies very well. However, the long term simulations from the final model did not match with literature reports. A modification is suggested based on the physiological understanding of the system. The proposed novel modification to precursor models can be of general use for predicting long term responses.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Cook T., Sheridan W.P.(2000). Development of GnRH antagonists for prostate cancer: new approaches to treatment. Oncologist 5:162–168
Parker S.L., Tong T., Bolden S., Wingo P.A.(1997). Cancer statistics, 1997. CA Cancer J. Clin. 47:5–27
Dutta R.S., Philip J., Javle P.(2005). Trends in prostate cancer incidence and survival in various socioeconomic classes: a population-based study. Int. J. Urol. 12:644–653
Labrie F., Belanger A., Luu-The V., Labrie C., Simard J., Cusan L., Gomez J., Candas B. (2005). Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr. Rev. 26:361–379
Klingmuller D., Schweikert H.U.(1992). Gonadotropin-releasing hormone: physiological and endocrinological aspects. Recent Results Cancer Res. 124:1–6
Plenaxis. Abarelix package insert. CDER Freedom of Information, http://www.fda.gov/ cder/foi/label/2003/021320lbl.pdf. 2003. 10-4-2005.
Broqua P., Riviere P.J., Conn P.M., Rivier J.E., Aubert M.L., Junien J.L.(2002). Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix. J Pharmacol. Exp. Ther. 301:95–102
Nagaraja N.V., Pechstein B., Erb K., Klipping C., Hermann R., Niebch G., Derendorf H.(2000). Pharmacokinetic and pharmacodynamic modeling of cetrorelix, an LH-RH antagonist, after subcutaneous administration in healthy premenopausal women. Clin. Pharmacol. Ther. 68:617–625
Pechstein B., Nagaraja N.V., Hermann R., Romeis P., Locher M., Derendorf H.(2000). Pharmacokinetic–pharmacodynamic modeling of testosterone and luteinizing hormone suppression by cetrorelix in healthy volunteers. J Clin. Pharmacol. 40:266–274
Wong S.L., Lau D.T., Baughman S.A., Menchaca D., Garnick M. B.(2003). Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer. Clin. Pharmacol. Ther. 73:304–311
Wong S.L., Lau D.T., Baughman S.A., Fotheringham N., Menchaca D., Garnick M.B. (2004). Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75. J Clin. Pharmacol. 44:495–502
Tornoe C.W., Agerso H., Nielsen H.A., Madsen H., Jonsson E.N.(2004). Pharmacokinetic/pharmacodynamic modelling of GnRH antagonist degarelix: a comparison of the non-linear mixed-effects programs NONMEM and NLME. J Pharmacokinet. Pharmacodyn. 31:441–461
Fattinger K.E., Verotta D., Porchet H.C., Munafo A., Le Cotonnec J.Y., SheinerL.B.(1996). Modeling a bivariate control system: LH and testosterone response to the GnRH antagonist antide. Am. J. Physiol. 271:E775–E787
C. W. Tornoe, H. Agerso, T. Senderovitz, H. A. Nielsen, H. Madsen, and E. N. Population PK/PD modelling of the hypothalamic–pituitary–gonadal axis following treatment with GnRH analogues. BJCP (2005) (submitted).
S. Melmed and D. L. Kleinberg. In P. R. Larsen, H. M. Kronenberg, S. Melmed, and K. S. Polonsky (eds.) Williams Textbook of Endocrinology, Saunders, Philadelphia (2002).
Clarke I.J., Cummins J.T.(1982). The temporal relationship between gonadotropin releasing hormone (GnRH) and luteinizing hormone (LH) secretion in ovariectomized ewes. Endocrinology 111:1737–1739
Yen S.S., Tsai C.C., Naftolin F., Vandenberg G., Ajabor L.(1972). Pulsatile patterns of gonadotropin release in subjects with and without ovarian function. J Clin. Endocrinol. Metab 34:671–675
Bergendahl M., Evans W.S., Veldhuis J.D.(1996). Current concepts on ultradian rhythms of luteinizing hormone secretion in the human. Hum. Reprod. Update. 2:507–518
Urban R.J., Evans W.S., Rogol A.D., Kaiser D.L., Johnson M.L., Veldhuis J.D.(1988). Contemporary aspects of discrete peak-detection algorithms. I. The paradigm of the luteinizing hormone pulse signal in men. Endocr. Rev. 9:3–37
Veldhuis J.D., King J.C., Urban R.J., Rogol A.D., Evans W.S., Kolp L.A., Johnson M.L.(1987). Operating characteristics of the male hypothalamo-pituitary–gonadal axis: pulsatile release of testosterone and follicle-stimulating hormone and their temporal coupling with luteinizing hormone. J Clin. Endocrinol. Metab. 65:929–941
Agerso H., Koechling W., Knutsson M., Hjortkjaer R., Karlsson M.O.(2003). The dosing solution influence on the pharmacokinetics of degarelix, a new GnRH antagonist, after s.c. administration to beagle dogs. Eur. J Pharm. Sci. 20:335–340
Keenan D.M., Sun W.M., Veldhuis J.D. (2000).A stochastic biomathematical model of the male reproductive hormone system. Siam J. Appl. Math. 61:934–965
Sharma A., Ebling W.F., Jusko W.J.(1998). Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. J Pharm. Sci. 87:1577–1584
Movin-Osswald G., Hammarlund-Udenaes M.(1995). Prolactin release after remoxipride by an integrated pharmacokinetic–pharmacodynamic model with intra- and interindividual aspects. J Pharmacol. Exp. Ther. 274:921–927
Huirne J.A., Lambalk C.B.(2001). Gonadotropin-releasing-hormone-receptor antagonists. Lancet 358:1793–1803
Cattanach B.M., Iddon C.A., Charlton H.M., Chiappa S.A., Fink G.(1977). Gonadotrophin-releasing hormone deficiency in a mutant mouse with hypogonadism. Nature 269:338–340
Schanbacher B.D., English H.F., Gross D., Santen R.J., Walker M.F., Falvo R.E.(1983). Animal model of isolated gonadotropin deficiency. I. Hormonal responses to LHRH immunoneutralization. J Androl 4:233–239
Iovane A., Aumas C., de Roux N.(2004). New insights in the genetics of isolated hypogonadotropic hypogonadism. Eur. J. Endocrinol. 151(Suppl 3):U83–U88
Jiang G., Stalewski J., Galyean R., Dykert J., Schteingart C., Broqua P., Aebi A., Aubert M.L., Semple G., Robson P., Akinsanya K., Haigh R., Riviere P., Trojnar J., Junien J.L., Rivier J.E.(2001). GnRH antagonists: a new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6. J. Med. Chem. 44:453–467
Jeyakumar M., Suresh R., Krishnamurthy H.N., Moudgal N.R.(1995). Changes in testicular function following specific deprivation of LH in the adult male rabbit. J. Endocrinol. 147:111–120
Singh A.B., Norris K., Modi N., Sinha-Hikim I., Shen R., Davidson T., Bhasin S. (2001). Pharmacokinetics of a transdermal testosterone system in men with end stage renal disease receiving maintenance hemodialysis and healthy hypogonadal men. J. Clin. Endocrinol. Metab. 86:2437–2445
Miyatake A., Morimoto Y., Oishi T., Hanasaki N., Sugita Y., Iijima S., Teshima Y., Hishikawa Y., Yamamura Y.(1980). Circadian rhythm of serum testosterone and its relation to sleep: comparison with the variation in serum luteinizing hormone, prolactin, and cortisol in normal men. J. Clin. Endocrinol. Metab. 51:1365–1371
Author information
Authors and Affiliations
Corresponding author
Additional information
The views expressed in this article are those of the authors and do not necessarily reflect the official views of FDA.
Rights and permissions
About this article
Cite this article
Jadhav, P.R., Agersø, H., Tornøe, C.W. et al. Semi-Mechanistic Pharmacodynamic Modeling for Degarelix, a Novel Gonadotropin Releasing Hormone (GnRH) Blocker. J Pharmacokinet Pharmacodyn 33, 609–634 (2006). https://doi.org/10.1007/s10928-006-9025-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10928-006-9025-1